Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 70

1.

Coordinate transcriptional regulation by ERG and androgen receptor in fusion-positive prostate cancers.

Chen Y, Sawyers CL.

Cancer Cell. 2010 May 18;17(5):415-6. doi: 10.1016/j.ccr.2010.04.022.

2.
3.

An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression.

Yu J, Yu J, Mani RS, Cao Q, Brenner CJ, Cao X, Wang X, Wu L, Li J, Hu M, Gong Y, Cheng H, Laxman B, Vellaichamy A, Shankar S, Li Y, Dhanasekaran SM, Morey R, Barrette T, Lonigro RJ, Tomlins SA, Varambally S, Qin ZS, Chinnaiyan AM.

Cancer Cell. 2010 May 18;17(5):443-54. doi: 10.1016/j.ccr.2010.03.018.

4.

Defining the molecular action of HDAC inhibitors and synergism with androgen deprivation in ERG-positive prostate cancer.

Björkman M, Iljin K, Halonen P, Sara H, Kaivanto E, Nees M, Kallioniemi OP.

Int J Cancer. 2008 Dec 15;123(12):2774-81. doi: 10.1002/ijc.23885.

5.

A transcriptional repressor co-regulatory network governing androgen response in prostate cancers.

Chng KR, Chang CW, Tan SK, Yang C, Hong SZ, Sng NY, Cheung E.

EMBO J. 2012 Jun 13;31(12):2810-23. doi: 10.1038/emboj.2012.112. Epub 2012 Apr 24.

6.

ERG induces androgen receptor-mediated regulation of SOX9 in prostate cancer.

Cai C, Wang H, He HH, Chen S, He L, Ma F, Mucci L, Wang Q, Fiore C, Sowalsky AG, Loda M, Liu XS, Brown M, Balk SP, Yuan X.

J Clin Invest. 2013 Mar;123(3):1109-22. doi: 10.1172/JCI66666. Epub 2013 Feb 15.

7.

1{alpha},25-Dihydroxyvitamin D3 inhibits growth of VCaP prostate cancer cells despite inducing the growth-promoting TMPRSS2:ERG gene fusion.

Washington MN, Weigel NL.

Endocrinology. 2010 Apr;151(4):1409-17. doi: 10.1210/en.2009-0991. Epub 2010 Feb 10.

8.

Abnormal expression of the ERG transcription factor in prostate cancer cells activates osteopontin.

Flajollet S, Tian TV, Flourens A, Tomavo N, Villers A, Bonnelye E, Aubert S, Leroy X, Duterque-Coquillaud M.

Mol Cancer Res. 2011 Jul;9(7):914-24. doi: 10.1158/1541-7786.MCR-10-0537. Epub 2011 Jun 13.

9.

ERG immunohistochemistry is not predictive for PSA recurrence, local recurrence or overall survival after radical prostatectomy for prostate cancer.

Hoogland AM, Jenster G, van Weerden WM, Trapman J, van der Kwast T, Roobol MJ, Schröder FH, Wildhagen MF, van Leenders GJ.

Mod Pathol. 2012 Mar;25(3):471-9. doi: 10.1038/modpathol.2011.176. Epub 2011 Nov 11.

10.

Relation of ETS transcription factor family member ERG, androgen receptor and topoisomerase 2β expression to TMPRSS2-ERG fusion status in prostate cancer.

Kolar Z, Burdova A, Jamaspishvili T, Bouchal J, Kucerova R, Bienova M, Kral M, Student V.

Neoplasma. 2014;61(1):9-16.

PMID:
24195515
11.

Androgens Induce Functional CXCR4 through ERG Factor Expression in TMPRSS2-ERG Fusion-Positive Prostate Cancer Cells.

Cai J, Kandagatla P, Singareddy R, Kropinski A, Sheng S, Cher ML, Chinni SR.

Transl Oncol. 2010 Jun 1;3(3):195-203.

12.

N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer.

Pflueger D, Rickman DS, Sboner A, Perner S, LaFargue CJ, Svensson MA, Moss BJ, Kitabayashi N, Pan Y, de la Taille A, Kuefer R, Tewari AK, Demichelis F, Chee MS, Gerstein MB, Rubin MA.

Neoplasia. 2009 Aug;11(8):804-11.

13.

Role of the TMPRSS2-ERG gene fusion in prostate cancer.

Tomlins SA, Laxman B, Varambally S, Cao X, Yu J, Helgeson BE, Cao Q, Prensner JR, Rubin MA, Shah RB, Mehra R, Chinnaiyan AM.

Neoplasia. 2008 Feb;10(2):177-88.

14.

Role of TMPRSS2-ERG gene fusion in negative regulation of PSMA expression.

Yin L, Rao P, Elson P, Wang J, Ittmann M, Heston WD.

PLoS One. 2011;6(6):e21319. doi: 10.1371/journal.pone.0021319. Epub 2011 Jun 24.

15.

Relation of ETS transcription factor family member ERG, androgen receptor and topoisomerase 2β expression to TMPRSS2-ERG fusion status in prostate cancer.

Kolar Z, Burdova A, Jamaspishvili T, Bouchal J, Kucerova R, Bienova M, Kral M, Student V.

Neoplasma. 2013 Sep 20. doi: 10.4149/neo_2014_004. [Epub ahead of print]

PMID:
24050545
16.

ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy.

Minner S, Enodien M, Sirma H, Luebke AM, Krohn A, Mayer PS, Simon R, Tennstedt P, Müller J, Scholz L, Brase JC, Liu AY, Schlüter H, Pantel K, Schumacher U, Bokemeyer C, Steuber T, Graefen M, Sauter G, Schlomm T.

Clin Cancer Res. 2011 Sep 15;17(18):5878-88. doi: 10.1158/1078-0432.CCR-11-1251. Epub 2011 Jul 26.

17.

YK-4-279 inhibits ERG and ETV1 mediated prostate cancer cell invasion.

Rahim S, Beauchamp EM, Kong Y, Brown ML, Toretsky JA, Üren A.

PLoS One. 2011 Apr 29;6(4):e19343. doi: 10.1371/journal.pone.0019343.

18.

Molecular characterization of TMPRSS2-ERG gene fusion in the NCI-H660 prostate cancer cell line: a new perspective for an old model.

Mertz KD, Setlur SR, Dhanasekaran SM, Demichelis F, Perner S, Tomlins S, Tchinda J, Laxman B, Vessella RL, Beroukhim R, Lee C, Chinnaiyan AM, Rubin MA.

Neoplasia. 2007 Mar;9(3):200-6.

19.

ETS transcription factors control transcription of EZH2 and epigenetic silencing of the tumor suppressor gene Nkx3.1 in prostate cancer.

Kunderfranco P, Mello-Grand M, Cangemi R, Pellini S, Mensah A, Albertini V, Malek A, Chiorino G, Catapano CV, Carbone GM.

PLoS One. 2010 May 10;5(5):e10547. doi: 10.1371/journal.pone.0010547.

20.

TMPRSS2-ERG-mediated feed-forward regulation of wild-type ERG in human prostate cancers.

Mani RS, Iyer MK, Cao Q, Brenner JC, Wang L, Ghosh A, Cao X, Lonigro RJ, Tomlins SA, Varambally S, Chinnaiyan AM.

Cancer Res. 2011 Aug 15;71(16):5387-92. doi: 10.1158/0008-5472.CAN-11-0876. Epub 2011 Jun 15.

Supplemental Content

Support Center